Cim Investment Mangement Inc. lowered its stake in LivaNova PLC (NASDAQ:LIVN) by 20.0% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 6,702 shares of the company’s stock after selling 1,676 shares during the quarter. Cim Investment Mangement Inc.’s holdings in LivaNova were worth $669,000 at the end of the most recent quarter.
A number of other hedge funds also recently made changes to their positions in LIVN. OppenheimerFunds Inc. lifted its position in LivaNova by 20,599.5% in the first quarter. OppenheimerFunds Inc. now owns 1,208,021 shares of the company’s stock valued at $106,909,000 after purchasing an additional 1,202,185 shares during the last quarter. Wells Fargo & Company MN raised its holdings in shares of LivaNova by 149.9% during the first quarter. Wells Fargo & Company MN now owns 895,623 shares of the company’s stock valued at $79,263,000 after acquiring an additional 537,282 shares in the last quarter. Point72 Asset Management L.P. bought a new position in shares of LivaNova during the first quarter valued at approximately $46,092,000. Rothschild Asset Management Inc. bought a new position in shares of LivaNova during the first quarter valued at approximately $35,753,000. Finally, BlackRock Inc. raised its holdings in shares of LivaNova by 6.0% during the first quarter. BlackRock Inc. now owns 5,083,877 shares of the company’s stock valued at $449,923,000 after acquiring an additional 287,262 shares in the last quarter. Hedge funds and other institutional investors own 85.14% of the company’s stock.
A number of equities analysts recently commented on the company. Stifel Nicolaus restated a “buy” rating and set a $135.00 target price on shares of LivaNova in a report on Thursday, August 2nd. ValuEngine upgraded LivaNova from a “buy” rating to a “strong-buy” rating in a report on Wednesday, May 2nd. BidaskClub upgraded LivaNova from a “buy” rating to a “strong-buy” rating in a report on Thursday, July 26th. Needham & Company LLC restated a “buy” rating and set a $135.00 target price (up previously from $128.00) on shares of LivaNova in a report on Wednesday, August 1st. Finally, Zacks Investment Research upgraded LivaNova from a “sell” rating to a “hold” rating in a report on Wednesday, July 4th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, four have given a buy rating and two have assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $95.14.
Shares of LivaNova stock opened at $122.90 on Wednesday. The company has a quick ratio of 1.08, a current ratio of 1.51 and a debt-to-equity ratio of 0.03. The company has a market cap of $5.98 billion, a P/E ratio of 37.13, a price-to-earnings-growth ratio of 3.54 and a beta of 0.88. LivaNova PLC has a 52 week low of $60.22 and a 52 week high of $124.97.
LivaNova (NASDAQ:LIVN) last issued its quarterly earnings results on Wednesday, August 1st. The company reported $0.96 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.92 by $0.04. The company had revenue of $287.50 million for the quarter, compared to analysts’ expectations of $278.08 million. LivaNova had a positive return on equity of 9.24% and a negative net margin of 4.93%. The firm’s revenue for the quarter was up 12.4% on a year-over-year basis. During the same period in the prior year, the firm earned $0.93 earnings per share. equities analysts predict that LivaNova PLC will post 3.24 earnings per share for the current fiscal year.
LivaNova Company Profile
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates in two segments, Cardiac Surgery and Neuromodulation. The Cardiac Surgery segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and accessories for extracorporeal circulation, and systems for autotransfusion and autologous blood washing, as well as surgical tissue and mechanical heart valve replacements, and repair products for damaged or diseased heart valves.
Recommended Story: Why Dividend Stocks May Be Right for You
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.